Tags

Type your tag names separated by a space and hit enter

Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Eur Child Adolesc Psychiatry. 2019 Nov 22 [Online ahead of print]EC

Abstract

This network meta-analysis assessed the efficacy and tolerability of lurasidone versus other oral atypical antipsychotic monotherapies in adolescent schizophrenia. A systematic literature review identified 13 randomized controlled trials of antipsychotics in adolescents with schizophrenia-spectrum disorders. A Bayesian network meta-analysis compared lurasidone to aripiprazole, asenapine, clozapine, olanzapine, paliperidone extended-release (ER), quetiapine, risperidone, and ziprasidone. Outcomes included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), weight gain, all-cause discontinuation, extrapyramidal symptoms (EPS), and akathisia. Results were reported as median differences for continuous outcomes and odds ratios (ORs) for binary outcomes, along with 95% credible intervals (95% CrI). Lurasidone was significantly more efficacious than placebo on the PANSS (- 7.95, 95% CrI - 11.76 to - 4.16) and CGI-S (- 0.44, 95% CrI - 0.67 to - 0.22) scores. Lurasidone was associated with similar weight gain to placebo and statistically significantly less weight gain versus olanzapine (- 3.62 kg, 95% CrI - 4.84 kg to - 2.41 kg), quetiapine (- 2.13 kg, 95% CrI - 3.20 kg to - 1.08 kg), risperidone (- 1.16 kg, 95% CrI - 2.14 kg to - 0.17 kg), asenapine (- 0.98 kg, 95% CrI - 1.71 kg to - 0.24 kg), and paliperidone ER (- 0.85 kg, 95% CrI - 1.57 kg to - 0.14 kg). The odds of all-cause discontinuation were significantly lower for lurasidone than aripiprazole (OR = 0.28, 95% CrI 0.10-0.76) and paliperidone ER (OR = 0.25, 95% CrI 0.08-0.81) and comparable to other antipsychotics. Rates of EPS and akathisia were similar for lurasidone and other atypical antipsychotics. In this network meta-analysis of atypical antipsychotics in adolescent schizophrenia, lurasidone was associated with similar efficacy, less weight gain, and lower risk of all-cause discontinuation compared to other oral atypical antipsychotics.

Authors+Show Affiliations

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón. IiSGM, School of Medicine, Universidad Complutense, CIBERSAM. Av. Séneca 2, 28040, Madrid, Spain.Sunovion Pharmaceuticals Inc, 84 Waterford Drive, Marlborough, MA, 01752, USA. Daisy.Ng-Mak@Sunovion.com.IQVIA, 210 Pentonville Rd, London, N1 9JY, UK.IQVIA, 210 Pentonville Rd, London, N1 9JY, UK.Sunovion Pharmaceuticals Inc, One Bridge Plaza North, Suite 510, Fort Lee, NJ, 07024, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31758359

Citation

Arango, Celso, et al. "Lurasidone Compared to Other Atypical Antipsychotic Monotherapies for Adolescent Schizophrenia: a Systematic Literature Review and Network Meta-analysis." European Child & Adolescent Psychiatry, 2019.
Arango C, Ng-Mak D, Finn E, et al. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. Eur Child Adolesc Psychiatry. 2019.
Arango, C., Ng-Mak, D., Finn, E., Byrne, A., & Loebel, A. (2019). Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-019-01425-2
Arango C, et al. Lurasidone Compared to Other Atypical Antipsychotic Monotherapies for Adolescent Schizophrenia: a Systematic Literature Review and Network Meta-analysis. Eur Child Adolesc Psychiatry. 2019 Nov 22; PubMed PMID: 31758359.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. AU - Arango,Celso, AU - Ng-Mak,Daisy, AU - Finn,Elaine, AU - Byrne,Aidan, AU - Loebel,Antony, Y1 - 2019/11/22/ PY - 2019/04/21/received PY - 2019/10/12/accepted PY - 2019/11/24/entrez PY - 2019/11/24/pubmed PY - 2019/11/24/medline KW - Adolescent KW - Body weight changes KW - Lurasidone KW - Network meta-analysis KW - Schizophrenia JF - European child & adolescent psychiatry JO - Eur Child Adolesc Psychiatry N2 - This network meta-analysis assessed the efficacy and tolerability of lurasidone versus other oral atypical antipsychotic monotherapies in adolescent schizophrenia. A systematic literature review identified 13 randomized controlled trials of antipsychotics in adolescents with schizophrenia-spectrum disorders. A Bayesian network meta-analysis compared lurasidone to aripiprazole, asenapine, clozapine, olanzapine, paliperidone extended-release (ER), quetiapine, risperidone, and ziprasidone. Outcomes included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), weight gain, all-cause discontinuation, extrapyramidal symptoms (EPS), and akathisia. Results were reported as median differences for continuous outcomes and odds ratios (ORs) for binary outcomes, along with 95% credible intervals (95% CrI). Lurasidone was significantly more efficacious than placebo on the PANSS (- 7.95, 95% CrI - 11.76 to - 4.16) and CGI-S (- 0.44, 95% CrI - 0.67 to - 0.22) scores. Lurasidone was associated with similar weight gain to placebo and statistically significantly less weight gain versus olanzapine (- 3.62 kg, 95% CrI - 4.84 kg to - 2.41 kg), quetiapine (- 2.13 kg, 95% CrI - 3.20 kg to - 1.08 kg), risperidone (- 1.16 kg, 95% CrI - 2.14 kg to - 0.17 kg), asenapine (- 0.98 kg, 95% CrI - 1.71 kg to - 0.24 kg), and paliperidone ER (- 0.85 kg, 95% CrI - 1.57 kg to - 0.14 kg). The odds of all-cause discontinuation were significantly lower for lurasidone than aripiprazole (OR = 0.28, 95% CrI 0.10-0.76) and paliperidone ER (OR = 0.25, 95% CrI 0.08-0.81) and comparable to other antipsychotics. Rates of EPS and akathisia were similar for lurasidone and other atypical antipsychotics. In this network meta-analysis of atypical antipsychotics in adolescent schizophrenia, lurasidone was associated with similar efficacy, less weight gain, and lower risk of all-cause discontinuation compared to other oral atypical antipsychotics. SN - 1435-165X UR - https://www.unboundmedicine.com/medline/citation/31758359/Lurasidone_compared_to_other_atypical_antipsychotic_monotherapies_for_adolescent_schizophrenia:_a_systematic_literature_review_and_network_meta-analysis L2 - https://dx.doi.org/10.1007/s00787-019-01425-2 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.